The President of Colombia, Ivan Duque, has stated that the country's food and drug regulator, the National Institute of Food and Drug Surveillance (Invima), authorised emergency use of Pfizer Inc and BioNTech SE's COVID-19 vaccine on 5 January 2021, Reuters news agency reported on Wednesday.
Colombia now awaits approval for the COVID-19 vaccines produced by AstraZeneca and Johnson & Johnson's pharmaceutical unit Janssen, Duque added.
Reportedly, patients aged 60 and over, or with co-morbidities such as asthma and diabetes, will be among the first in line for vaccines, along with health workers.
Colombia has agreed to buy 10 million doses each of the Pfizer-BioNTech and AstraZeneca COVID-19 vaccines, as well as nine million from Janssen. It has also secured 20 million vaccine doses via the World Health Organisation-backed COVAX mechanism.
According to Colombia's minister of health, the first delivery of 1.7 million Pfizer-BioNTech vaccine doses is expected in February 2021.
Colombia aims to vaccinate 35.7 million of its 50 million inhabitants.
So far, Colombia has reported 1.7 million COVID-19 infections and 44,426 deaths.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies